Document:

Prepared by MerrillDirect

EXHIBIT 10.19

AGREEMENT FOR WAFER PRODUCTION
AND TESTING

between

Advanced Power Technology, Inc.

and

Episil Technologies, Inc.

[ * ] = Confidential treatment
requested.

             This
Agreement (“Agreement”) is entered into by Advanced Power Technology, Inc.; a
Delaware Corporation with headquarters located at 405 SW Columbia Street in
Bend, Oregon, USA (hereinafter referred to as “APT”)

and

Episil Technologies, Inc., a Taiwan
Corporation with headquarters located at No 5 Creation  Road II, Science Based Industrial Park in
Hsin-Chu, Taiwan (hereinafter referred to as “EPISIL”).

RECITALS

             WHEREAS APT owns certain intellectual
property rights to the technology and design methods used in the design and
manufacture of APT’s Power MOS semiconductors.

             WHEREAS APT desires EPISIL to produce and
supply die to APT in the form of fully processed wafers (including wafer
thinning, backside implant and backside metalization).

             WHEREAS EPISIL desires to produce and
supply fully processed wafers to APT upon the terms and conditions contained in
this Agreement.

             WHEREAS
both parties seek to enter into a long-term business relationship where EPISIL
produces wafers / dies conforming to APT’s present and future technologies.
These technologies include but are not limited to [*].

             WHEREAS APT understands and EPISIL agrees
that production ramp-up will commence in EPISIL’s facility located in Hsin-Chu,
Taiwan and that the initial wafer diameter will be [*]

             WHEREAS Episil agrees to install [*]

             WHEREAS APT understands and EPISIL agrees
that production capacity will be made available to APT through either capacity
expansions at EPISIL’s facility in Hsin-Chu, Taiwan or through manufacturing
capability established by EPISIL in other locations including the possibility
of the location being in China.

             WHEREAS both parties agree to cooperate in
order to continuously improve the outgoing quality of wafers manufactured
pursuant to this Agreement.

             NOW THEREFORE, based on mutual promises
contained herein and intending to be legally bound, EPISIL and APT agree as
follows:

 

	1.	DEFINITIONS
	 	 
	1.1	“Power MOS-Die” shall
  mean part numbers listed and specified in Exhibit 1, to be
  manufactured by EPISIL for APT.  Exhibit
  1 may be amended or modified in numbers and types from time to time by
  agreement between APT and EPISIL.
	 	 
	1.2	“Product Information
  Package” shall mean the technical information (e.g. database tape, test
  program, etc.) and hardware utilities specified in Exhibit 2 to be
  provided to EPISIL by APT for each Power MOS Die.
	 	 
	1.3	“Process” shall mean a
  manufacturing process which has been mutually accepted by APT and EPISIL and
  which has been specified in Exhibit 3, to be used by EPISIL for the
  purpose of manufacturing Wafers exclusively for APT.
	 	 
	1.4	“Wafers” shall mean
  silicon wafers with Power MOS Die manufactured by EPISIL using the Processes
  and design and database of the Product Information Package.
	 	 
	1.5	“Good Die” shall mean
  a Die on a Wafer which meets the specifications as per Exhibits 3 and 4,
  and which fully satisfies the relevant test program for Wafer test, supplied
  by APT.
	 	 
	1.6	“Proprietary
  Information” shall mean any and all information including but not limited to
  technical information, database tapes, specifications, test tapes and
  supporting documentation provided either orally, in writing, or in machine
  readable format and reticles or masks generated by or for EPISIL using the
  Product Information Package; provided that all such information is marked
  “Confidential” or similarly, or, if oral, identified as proprietary at time
  of disclosure and reduced to writing within thirty (30) days thereafter.  Additionally, the parties agree that this
  Agreement and its Exhibits as such and the content thereof shall be kept
  confidential except as required to comply with U.S. Securities and Exchange
  Commission rules and regulations and applicable stock exchange rules.  Notwithstanding the foregoing Proprietary
  Information does not include information generally available to the public,
  information independently developed or known by the receiving party without
  reference to information disclosed hereunder, information rightfully received
  from a third party without breach of confidentiality obligations, or
  information authorized in writing for release by the disclosing party
  hereunder.
	 	 
	1.7	“Risk Start” shall
  mean production of Wafers before qualification, defined in Section 2.3, has
  been completed.
	 	 
	2.	PROCESS TECHNOLOGY, MASKS, QUALIFICATION, WAFER TEST
	 	 
	2.1	PROCESS TECHNOLOGY
	 	 
	 	 	2.1.1     APT shall provide EPISIL with the design
  information for each Process as described in Exhibit 2 for the purpose
  of specifying the Process in accordance with Section 2.1.2.
	 	 
	 	 	2.1.2     Both parties agree that technology
  transfer and qualification will proceed first on APT’s [*] products / process
  with the intent that Processes are qualified for each technology listed in
  Exhibit 5 within [*] months of the date this Agreement is executed.
	 	 
	 	 	             APT
  and EPISIL shall agree upon Process specifications to be described in Exhibit
  3, which shall be finalized before EPISIL begins production in accordance
  with Section 3.
	 	 
	 	 	             Subject
  to the stipulations and procedures set forth in this Agreement and in
  accordance with the qualification plan described in Exhibit 4, EPISIL
  shall install the Processes meeting the specifications in Exhibit 3
  and deliver Wafers for qualification purposes.
	 	 
	2.2	MASKS
	 	 
	 	 	2.2.1     [*]
	 	 
	 	 	2.2.2     EPISIL will provide APT with sufficient
  information such that APT can incorporate EPISIL’s alignment structures into
  the mask database.  EPISIL may also
  choose to add the alignment marks or have them added by a third party [*]
	 	 
	 	 	2.2.3     APT will supply mask databases to
  EPISIL or EPISIL’s designated mask vendor.
	 	 
	 	 	2.2.4     EPISIL will pay for subsequent masks
  worn out or broken during the normal course of production.  EPISIL will also pay for any masks
  redesigned upon EPISIL’s request.
		 
	2.3	QUALIFICATION
	 	 
	 	 	2.3.1     The qualification approval by APT for
  each Process and each individual Power MOS Die, manufactured with the
  Process, is a prerequisite for ordering and delivery of Wafers and/or Good
  Dies.  This Section 2.3.1 is not
  applicable in the case of Risk Starts.
	 	 
	 	 	2.3.2     APT will pay [*] for qualification
  wafers, which is defined in Exhibit 5.
	 	 
	 	 	2.3.3     A wafer lot will be considered as
  “qualification worthy” only if it has a probe yield of at least [*] of the
  yield obtained by APT’s own wafer fab during the prior quarter.  APT may choose to waive this requirement
  at its own discretion.
	 	 
	 	 	2.3.4     For the purpose of qualification as
  specified in Exhibit 4, EPISIL shall provide APT, with the agreed upon
  number of Wafers.  Such Wafers
  delivered for qualification must also meet all agreed APT standards,
  specifications and requirements defined in the Exhibits 1, 2, 3 and 4
  provided, however, that if failures occur due to reasons for which APT is
  responsible, EPISIL shall be paid 100% of the Wafer price as specified in Exhibit
  5.  EPISIL shall, in accordance
  with the agreed schedule, deliver to APT any documents and reports as
  required.
	 	 
	 	 	2.3.5     Prior to completion of the
  qualification, APT may request that EPISIL provides Wafers out of “Risk
  Starts”.  EPISIL will provide these
  Wafers out of Risk Starts to APT at the price/volume specified in Exhibit
  5.
	 	 
	 	 	2.3.6     During qualification, APT may stop
  production of Wafers for any or all APT Power MOS Die by giving written
  notice to EPISIL.  EPISIL will stop
  production following completion of the process step at which the Wafer
  resides at the time of such written notification.  APT will pay EPISIL for all Wafers started prior to EPISIL
  receiving such notice.  Prices for
  such Wafers will be based on the stage of production of the Wafers as defined
  in Exhibit 5.
	 	 
	 	 	2.3.7     After APT qualification approval of a
  Process, EPISIL shall not carry out any major changes as defined by EPISIL’s
  internal standards unless approved by APT. 
  EPISIL may only carry out process changes upon written authorization
  from APT.
	 	 
	 	 	2.3.8     In the case that EPISIL desires to
  perform major changes to a Process, APT shall be informed in writing 9
  months, or a shorter period if mutually agreed upon, prior to the planned
  commencement of such changes to the Process and shall receive a detailed
  description of the planned changes in writing as well as the results of any
  re-qualification of the Process with the intended changes to be performed by
  EPISIL in accordance with Exhibits 2, 3 and 4.  APT will inform EPISIL in writing whether
  or not desired changes of the Process are acceptable.  In such case, a re-qualification of the
  Process, according to this Section 2.3, is necessary and EPISIL shall provide
  APT with the necessary Wafers for such re-qualification free of charge.  APT shall purchase the Wafers for
  re-qualification, if APT requests such changes to the Process.  Successful re-qualification is the
  prerequisite for final approval of APT to a major change to a Process.  APT shall not unreasonably deny its
  consent to a major change to a process requested by EPISIL and APT shall not
  withhold such consent absent clear proof that such change will have a
  material adverse effect on the resulting Power MOS Die (e.g., but not limited
  to yield, quality, reliability, specification of the respective Power MOS
  Die, or reasonable customer requests affecting a material quantity of
  Wafers).
	 	 
	 	 	2.3.9     The specifications and requirements
  specified in Exhibits 2, 3 and 4 may only be modified by mutual
  written agreement between EPISIL and APT.
	 	 
	 	 	2.3.10     If APT determines that modifications to
  the specifications are required, including modifications to photo masks,
  Process or testing, or next generation MOS technology, EPISIL shall perform
  such modifications at APT’s cost, which shall be reasonable.  Regarding modification of the Process, the
  parties have to agree to such proposed modifications in advance.  The parties will negotiate adjustment to
  production price and delivery schedule in advance if price or delivery
  schedule are affected by such modifications.
	 	 
	2.4	WAFER TESTING
	 	 
	 	 	2.4.1     The testing of Wafers will be performed
  by EPISIL.  For the purpose of yield
  improvement and for the calculation of pricing, EPISIL and APT will share all
  information related to wafer probe results.
	 	 
	3.	PRODUCTION, FORECAST/ORDERING
	 	 
	3.1	The business for each
  technology will be conducted [*].
	 	 
	3.2	Upon written notice
  from APT of successful completion of the qualification as described in
  Section 2, and having received a purchase order from APT, EPISIL shall
  manufacture and deliver Wafers according to the terms of this Agreement.
	 	 
	3.3	EPISIL will make a
  reasonable best effort to allocate capacity as required by APT during the
  contract period.  The start date for
  the contract will be the qualification date for the first production part for
  APT.  EPISIL agrees to provide a [*]
  confirmation of capacity which will be reserved for APT at the agreed upon
  terms of pricing and cycle time. Increases in capacity required by APT will
  be pre-negotiated with Episil by APT, and EPISIL agrees to give its
  reasonable best effort to install the additional capacity in EPISIL’s
  facilities.
	 	 
	3.4	APT agrees to provide
  a three-month rolling forecast of the gross number of wafer starts on a
  monthly basis.  This gross number is
  not required to be device specific. [*]
	 	 
	3.5	The purchase of Wafers
  and/or Good Die pursuant to this Agreement shall be accomplished by means of
  purchase orders, which will be issued to EPISIL on at least an annual basis
  and no more frequently than on a quarterly basis.  The new purchase will be based upon the APT forecast as well as
  past performance against the prior period’s purchase orders.
	 	 
	[Note – Sections 3.6
  and 3.7 intentionally not used]
	 	 
	3.8	APT will release to
  EPISIL device specific wafer starts by [*]
	 	 
	3.9	EPISIL agrees to
  provide starting material (epi wafers) pursuant to the forecasts received by
  APT.
	 	 
	3.10	It is anticipated that
  from time to time there will be instances where an accelerated cycle time is
  required to serve APT’s needs.  EPISIL
  will apply their best effort to meet such accelerated delivery schedules.
	 	 
	3.11	Both parties will
  immediately advise one another in writing whenever they have reason to
  believe that wafers may not conform to the applicable specifications.
	 	 
	3.12	In the case of
  technical problems arising in the processing of wafers, especially with
  regard to yield, quality, reliability, EPISIL shall notify APT in writing and
  APT will be prepared to assist EPISIL to a reasonable extent in solving the
  problem.
	 	 
	3.13	In case any technical
  problem, defect or malfunction should occur, which EPISIL will be informed
  about, EPISIL will immediately start investigations and supply a first
  substantiated answer or status report within seven (7) working days after
  receipt of APT’s notification of such matter.
	 	 
	3.13	In order to ensure
  traceability, processing and delivery of wafers and/or good die will be on a
  lot-by-lot basis unless otherwise agreed upon.  Should lot splitting be necessary, APT will be notified and
  given the opportunity to decide whether to recombine the sublots prior to
  delivery or not.
	 	 
	3.14	APT may request EPISIL
  to stop production at any time by giving written notice to EPISIL.  EPISIL will stop production following
  completion of the process step at which the wafers reside at the time of the
  notification from APT.  If the reason
  for such a stop of production is not attributable to a failure of EPISIL to
  fulfill its obligations under this Agreement, EPISIL will be paid for the
  wafers.  If such a stop of production
  is attributable to EPISIL failing to fulfill its obligations under this
  Agreement, only those Wafers that meet the criteria applicable to Production
  Wafers shall be paid for.
	 	 
	3.15	If any circumstances
  should arise that could result in a delayed delivery to APT, EPISIL shall
  promptly notify APT and EPISIL will make every reasonable effort to recover
  the original schedule.
	 	 
	4.	PRICES,
  PAYMENT, DELIVERIES AND SHIPMENTS
	 	 
	4.1.	Pricing for Wafers
  and/or Good Die are specified in Exhibit 5.  Prices are quoted in US currency.
	 	 
	4.2.	Payment shall be due
  30 days net after receipt by APT or one of its subsidiaries and the
  respective invoice from EPISIL.
	 	 
	4.3.	Payment of invoices
  will be split at Episil’s discretion and direction between more than one bank
  account. For example, a portion of the payment for an invoice may be paid to
  Episil’s Foundry agent in the US and the remaining portion to Episil.
	 	 
	4.4.	Subject to a
  respective purchase order of APT or one of its subsidiaries, Wafers and/or
  Good Die shall be delivered in accordance with the delivery specification to
  the address specified by APT.  APT
  may, without being obligated to, perform an incoming inspection.
	 	 
	5.	ON-SITE INSPECTION, DOCUMENTATION AND REPORTING
	 	 
	5.1	Subject to EPISIL’s
  standard safety and manufacturing procedures, employees of APT shall be
  allowed to visit EPISIL’s factory during normal working hours with reasonable
  prior written notice to EPISIL.  Such
  employees shall be granted access to EPISIL’s production flow and production
  control information regarding products being manufactured for APT.
	 	 
	5.2	Subject to mutually
  agreeable confidentiality protections and to EPISIL’s standard safety and
  manufacturing procedures, and upon APT’s written request reasonable in
  advance, EPISIL will allow APT representatives and/or APT customers to
  perform an audit of EPISIL’s production site and quality systems for
  Wafers.  Such audits shall not occur
  more than four (4) times per year and no more than two (2) times per quarter
  unless any such audit discovers material deficiency, in which case additional
  audits may be conducted by APT as often as reasonably requested by APT, until
  such deficiencies are corrected.
	 	 
	5.3	On written request,
  EPISIL shall provide reports to APT. 
  These reports may include work in process, ordered volumes and
  outgoing volumes, probe yield, probe rejects and parametric data.  The detailed procedure shall be fixed in
  writing separately.
	 	 
	5.4	Both parties shall
  maintain a clear organizational responsibility for execution of this
  Agreement with respect to technical, logistical as well as quality
  issues.  At least one person from each
  party will be nominated to cover the administration of this Agreement full
  time.
	 	 
	5.5	Each party agrees to
  pay all expenses associated with communication, travel, and accommodations
  while visiting or communicating with the other party.
	 	 
	6.	WARRANTY
	 	 
	6.1	EPISIL warrants that
  all Wafers and/or Good Die delivered hereunder will meet the applicable specifications
  and requirements in Exhibits 1, 2, 3 and 4 and shall be free from
  defects in material and workmanship.
	 	 
	6.2	[*]
	 	 
	6.3	[*]
	 	 
	6.4	If Wafers and/or Good
  Die fail to meet specifications in Exhibits 1, 2, 3 and 4, and in
  APT’s reasonable opinion such failure appears material, APT or one of its
  subsidiaries may request EPISIL to stop production.  If EPISIL is unable to correct such failures within 30 days,
  APT or the Subsidiary that has ordered may cancel such particular orders.
	 	 
	6.5	If defects or
  malfunctions appear to be of excessive or epidemic nature resulting from
  processing or the use of unsuitable materials by EPISIL, then EPISIL shall
  take appropriate actions to remedy such defects in agreement with APT and in
  accordance with industry standards applicable to the individual
  circumstances.  EPISIL shall inform
  APT in writing about its actions to be taken within two (2) weeks after
  notification. If APT finds these actions unacceptable then they can terminate
  the Agreement per Section 12.
	 	 
	6.6	The foregoing warranty
  constitutes EPISIL’s exclusive liability, and the exclusive remedy of APT,
  for any breach of any warranty or any nonconformity of the Wafers to the
  specifications.  This warranty is
  exclusive and in lieu of all other warranties, express, implied or statutory,
  including but not limited to the warranties for merchantability and fitness
  for a particular purpose, which are hereby expressly disclaimed.
	 	 
	7.	FORCE MAJEURE, LATE DELIVERIES
	 	 
	7.1	Neither party shall be
  liable to the other for failure or delay in the performance of any of its
  obligations under this Agreement for the time and to the extent such failure
  or delay is caused by Force Majeure such as, but not limited to, riots, civil
  commotions, wars, hostilities between nations, governmental laws, orders or
  regulations, actions by the government or any agency thereof, storms, fires,
  strikes, lockouts, sabotages or any other contingencies beyond the reasonable
  control of the respective party and of its subcontractors.  In such events, the affected party shall
  immediately inform the other party of such circumstances, together with
  documents of proof, and the performance of obligations hereunder shall be
  suspended during, but not longer than, the period of existence of such cause
  and the period reasonably required to perform the obligations in such cases.
	 	 
	7.2	In addition to any
  other rights, in case of a delay of delivery by one month caused by whatever
  reason including late deliveries of EPISIL’s vendors, APT shall be entitled
  to cancel the order delayed, in whole or in part, without incurring any
  liability, and may reorder the quantities according to then existing needs of
  APT.  APT will have no right to cancel
  purchase orders if the late delivery is due to a Force Majeure of less than
  two months or APT’s fault.
		 
	8.	PROPRIETARY INFORMATION
	 	 
	8.1	Both EPISIL and APT
  agree that Proprietary Information of the other will be used by them
  exclusively for the purpose of manufacturing Wafers and/or Good Dies
  hereunder and will not be disclosed to any third party without the prior
  written permission of the disclosing party.
	 	 
	8.2	EPISIL agrees to use
  reasonable care to maintain in confidence Proprietary Information of APT
  furnished hereunder, not to make use thereof other than for the purposes set
  forth in this Agreement, and not to distribute, disclose or disseminate
  Proprietary Information of APT in any way or form to anyone except its own
  employees who have a reasonable need to know the same provided, however, that
  this Agreement shall impose no obligation on EPISIL with respect to any
  Proprietary Information which:
	 	 
	 	 	a)     is already in the public domain or
  becomes available to the public through no breach by EPISIL;
	 	 
	 	 	b)     was rightfully in EPISIL’s possession without
  obligation of confidence prior to receipt from APT;
	 	 
	 	 	c)     was received by EPISIL from a third
  party without obligation of confidence;
	 	 
	 	 	d)     is independently developed by EPISIL
  without reference to information disclosed hereunder
	 	 
	 	 	e)     is approved for release by written
  Agreement of APT.
	 	 
	 	Each party
  acknowledges and agrees that in the course of performing under this
  Agreement, it shall have access to and become acquainted with information
  concerning various trade secrets and other confidential and Proprietary
  Information of the other party.  This
  includes, but is not limited to, marketing plans, the identities of suppliers
  and customers, ideas, design rules, secret inventions, unique processes,
  compilations of information, records, specifications and other information
  which is owned by the other party, and shall maintain such information in
  confidence and shall not apply this information either directly or indirectly
  without prior consent from the other party to any products not included in
  this Agreement.
	 	 
	8.3	EPISIL shall destroy
  all defective Wafers, Die and masks unless otherwise requested by APT in
  writing.  In the case of idle masks,
  excessive Wafers and/or Good Die, EPISIL will inform APT in writing and APT
  will give the disposition instructions in writing within thirty (30) days.
	 	 
	8.4	No press release or
  any publication of the existence of this Agreement shall be allowed unless
  first approved by the other party in writing, with such approval not being
  unreasonably withheld.
	 	 
	8.5	Upon written request
  by APT, EPISIL shall return or destroy all written Proprietary Information
  received, as well as all copies made of such Proprietary Information.
	 	 
	8.6	All Proprietary
  Information of APT shall remain the property of APT.  Any masks generated by EPISIL from APT
  database tapes shall be the property of APT, will be returned to APT or
  destroyed on APT’s written request, and will be used exclusively to produce
  Wafers and Good Die for APT.  Nothing
  contained in this Agreement shall be construed as granting any license or
  rights under any proprietary right whether present or future.  The disclosure of Proprietary Information
  shall not result in any obligation to grant EPISIL rights therein.
	 	 
	8.7	If APT is furnished
  hereunder with Proprietary Information of EPISIL, the stipulation of this
  Section 8 shall apply accordingly in the reverse relation between the
  parties.
	 	 
	8.8	Upon termination or
  expiration of this Agreement for whatever reason, the receiving party shall
  (i) return to the other party or destroy the original and all copies of any
  Proprietary Information and (ii) at the disclosing party’s request, have one
  of its officers certify in writing that it will not make any further use of
  such Proprietary Information and will not manufacture or have manufactured
  any product incorporating Proprietary Information.
	 	 
	9.	PATENT INDEMNITY, PRODUCT LIABILITY INDEMNITY
	 	 
	9.1	It is APT’s
  responsibility to defend or otherwise resolve at APT’s sole expense any
  dispute arising from a claim that the Power MOS Die infringe a third party’s
  patent, trademark, copyright, mask work rights, trade secret or other
  intellectual properties.
	 	 
	9.2	Notwithstanding
  Section 9.1 above, it is EPISIL’s responsibility to defend or otherwise
  resolve at EPISIL’s sole expense any dispute arising from a claim that the
  Wafers or Die infringe a third party’s patent, trademark, copyright, mask
  work rights, trade secret or other intellectual properties due solely to the
  Process used by EPISIL or its subcontractors to process the Wafers.
	 	 
	9.3	If a third party’s
  claim is made alleging an infringement of a patent, copyright or other
  intellectual properties of the said third party, then the party to this
  Agreement against which this claim is raised shall immediately inform the
  other party thereof in writing.
	 	 
	9.4	APT shall indemnify
  and hold EPISIL harmless against any third party claims, costs and expenses
  due to all liabilities that may arise from EPISIL’s use of know-how supplied
  by APT.
	 	 
	9.5	EPISIL shall indemnify
  and hold APT, its subsidiaries and its customers harmless against any third
  party claims, costs and expenses due to all liabilities that may arise due to
  reasons other than APT’s product liability as per Section 9.4 above.
	 	 
	9.6	The above liabilities
  of a party hereto to the other party are in any case under the condition that
  the other party notifies the first party of the respective third party’s
  claim without any reasonable delay and does not admit on its own initiative
  that said claim was rightfully raised.
	 	 
	9.7	The above liability
  shall be the sole and exclusive remedies between the parties with respect to
  patent indemnity and product liability.
	 	 
	10.	EXPORT REGULATIONS
	 	 
	10.1	APT’s Product
  Information Package, as well as supplies furnished under this Agreement, is
  subject to governmental export regulations. 
  Consequently, these obligations may be subject to the approval by the
  respective governmental authorities.
	 	 
	10.2	For presentation to
  the International Export Control Authorities, EPISIL declares that all APT
  Product Information Packages received by EPISIL from APT are intended for
  manufacturing of Wafers and Good Die exclusively for APT.  EPISIL declares not to export such APT
  Product Information Packages to third countries without approval of the
  competent U.S. Export Control Authorities.
	 	 
	11.	ASSIGNMENT
	 	 
	11.1	Neither party shall
  delegate any obligations under this Agreement, or assign this Agreement or
  any interest or rights hereunder without the prior written consent of the
  other, except incident to the Sale or transfer of substantially all of such
  party’s business.
	 	 
	11.2	APT’s obligations
  under this Agreement may be performed by its subsidiaries at APT’s
  discretion.
	 	 
	12. 	TERMS AND TERMINATION
	 	 
	12.1	This Agreement becomes
  effective with the execution hereof by both parties and shall remain in
  effect until terminated pursuant to the provisions of this Section 12.  During the duration of this agreement each
  party may terminate the Agreement with twenty-four (24) months prior written
  notice unless mutually agreed to reduce this notice time.
	 	 
	12.2	This Agreement may be
  terminated immediately by one party if the other party
	 	 
	 	 	(i)     breaches any material provision of this
  Agreement and does not remedy such breach within thirty (30) days of notice
  of breach; or
	 	 
	 	 	(ii)     becomes insolvent or otherwise subject
  to insolvency procedures;
	 	 
	 	 	(iii)     comes under outside control, i.e. 50%
  or more of the shareholders’ voting rights are held directly or indirectly by
  a third party or third parties that are direct competitors of the other
  party.
	 	 
	12.3	APT may terminate this
  Agreement if the Power MOS Die do not pass APT’s qualification criteria set
  forth in Exhibit 4 and provided APT has made a reasonable attempt to
  execute the qualification within 6 months after receipt of qualification
  wafers.
	 
	 	[Note – Section 12.4
  intentionally not used]
	 	 
	12.5	The provisions of
  Section 6, 8, 13 and 14 shall also apply after termination of this Agreement.
	 	 
	13.	ARBITRATION
	 	 
	 	Any controversy or
  claim arising out of or relating to this Agreement, including, without
  limitation, the making, performance, or interpretation of this Agreement,
  shall be settled by arbitration. 
  Unless otherwise agreed, the arbitration shall be conducted in Bend,
  Oregon, in accordance with the then-current Commercial Arbitration Rules of
  the American Arbitration Association. 
  The arbitration shall be held before a single arbitrator (unless
  otherwise agreed by the parties).  The
  arbitrator shall be chosen from a panel of attorneys knowledgeable in the
  field of business law in accordance with the then-current Commercial
  Arbitration Rules of the American Arbitration Association.  If the arbitration is commenced, the
  parties agree to permit discovery proceedings of the type provided by the
  Oregon Rules of Civil Procedure both in advance of, and during recesses of,
  the arbitration hearings.  The parties
  agree that the arbitrator shall have no jurisdiction to consider evidence
  with respect to or render an award or judgment for punitive damages (or any
  other amount awarded for the purpose of imposing a penalty).  The parties agree that all facts and other
  information relating to any arbitration arising under this Agreement shall be
  kept confidential to the fullest extent permitted by law.
	 	 
	14.	GOVERNING LAW
	 	 
	 	This Agreement shall
  be governed by and construed in accordance with the laws of the state of
  Oregon
	 	 
	15.	ATTORNEY FEES
	 	 
	 	If any suit or action
  is filed by any party to enforce this Agreement or otherwise with respect to
  the subject matter of this Agreement, the prevailing party shall be entitled
  to recover reasonable attorney fees incurred in preparation or in prosecution
  or defense of such suit or action as fixed by the trial court, and if any
  appeal is taken from the decision of the trial court, reasonable attorney
  fees as fixed by the appellate court.
	 	 
	16.	NOTICES
	 	 
	 	All notices required
  to be sent by either party under this Agreement will be sent to the addresses
  set forth below, or to such other address as may subsequently be designated
  in writing:
	 	 
	 	If to APT:

  Advanced Power Technology, Inc. 

  405 S.W. Columbia Street 

  Bend, Oregon 97702 USA 

  Attention:  Russell Crecraft 

  Title:  Vice President, Manufacturing
  Operations 

  Telephone:  (541) 382-8028 

  Fax: 541-330-3963 

  e-mail: russellc@advancedpower.com
	 	 
	 	If to EPISIL: 

  EPISIL, Inc. 

  No 5 Creation Road II 

  Science Based Industrial Park, 

  Hsin-Chu, Taiwan, R.O.C. 

  Attention:  K. S. Liao 

  Title:  Sales Manager, Sales Department,
  Device Foundry 

  Telephone:  (886)-3-579-0750 

  Fax: (886)-3-579-0750 

  e-mail: ksliao@episil.com
	 	 
	17.	AMENDMENTS
	 	 
	 	Only an instrument in
  writing executed by all the parties may amend this Agreement.
	 	 
	18.	ENTIRE AGREEMENT
	 	 
	 	This document is the
  entire understanding between EPISIL and APT with respect to the subject
  matter hereof and merges all prior Agreements, dealings and
  negotiations.  The terms of this
  Agreement shall govern the Sales and purchase of Wafers and Good Die.  The parties recognize that the Exhibits to
  this Agreement will have to be amended or exchanged, as the case may be, from
  time to time.  No modification,
  alteration or amendment shall be effective unless in writing and signed by both
  parties.  No waiver of any breach shall
  be held to be a waiver of any other or subsequent breach.

 

 

	AGREED TO:	 
	 	 
	Advanced Power
  Technology, Inc.	EPISIL, Inc.
	 	 
	By: Russell J.
  Crecraft	By: K.S. Liao
	 	 
	Title: Vice President,
  Manufacturing Operations	Title: Sales Manager
	 	 
	Date: March 7, 2001	Date: March 13, 2001

EXHIBIT 1: List of Die Types – [*]

 

 

EXHIBIT 2:  Specification of Processes

 

1.          APT
Lot Traveler

2.          APT Processing Specifications

3.          APT Material Specifications

4.          APT Control and Inspection
Specifications

5.          APT Mask Tooling, Procurement
and Inspection Specifications

6.          Test Programs

7.          Mask Database

EXHIBIT
3:  TBD

 

This exhibit will contain a mutually
agreed upon set of specifications to which EPISIL will produce wafers for APT.

 

EXHIBIT 4:  Qualification Plan and Procedure [*]

 

 

EXHIBIT 5: [*]Prepared by MerrillDirect

Exhibit 10.3

SCIENTIFIC
LEARNING CORPORATION

1999 EQUITY INCENTIVE PLAN

STOCK
OPTION AGREEMENT

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)

          Pursuant to your Notice of Grant of Stock
Options (“Grant Notice”) and this Stock Option Agreement, Scientific Learning
Corporation (the “Company”) has granted you an option under its 1999 Equity
Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s
Common Stock indicated in your Grant Notice at the exercise price indicated in
your Grant Notice.  Defined terms not
explicitly defined in this Stock Option Agreement but defined in the Plan shall
have the same definitions as in the Plan.

          The details of your option are as follows:

          1.       VESTING.  Subject to the limitations contained herein,
your option will vest as provided in your Grant Notice, provided that vesting
will cease upon the termination of your Continuous Service.

          2.       NUMBER
OF SHARES AND EXERCISE PRICE.  The number of shares of Common Stock subject
to your option and your exercise price per share referenced in your Grant
Notice may be adjusted from time to time for Capitalization Adjustments, as
provided in the Plan.

          3.       EXERCISE
PRIOR TO VESTING (“EARLY EXERCISE”).  If permitted in your Grant Notice (i.e.,
Schedule A indicates that “Early Exercise” of your option is permitted) and
subject to the provisions of your option, you may elect at any time that is
both (i) during the period of your Continuous Service and (ii) during the term
of your option, to exercise all or part of your option, including the nonvested
portion of your option; provided, however, that:

          (a)      a partial exercise of
your option shall be deemed to cover first vested shares of Common Stock and
then the earliest vesting installment of unvested shares of Common Stock;

          (b)      any shares of Common
Stock so purchased from installments that have not vested as of the date of
exercise shall be subject to the purchase option in favor of the Company as
described in the Company’s form of Early Exercise Stock Purchase Agreement;

          (c)      you shall enter into
the Company’s form of Early Exercise Stock Purchase Agreement with a vesting
schedule that will result in the same vesting as if no early exercise had
occurred; and

          (d)      if your option is an incentive stock option, then, as provided in the
Plan, to the extent that the aggregate Fair Market Value (determined at the
time of grant) of the shares of Common Stock with respect to which your option
plus all other incentive stock options you hold are exercisable for the first
time by you during any calendar year (under all plans of the Company and its
Affiliates) exceeds one hundred thousand dollars ($100,000), your option(s) or
portions thereof that exceed such limit (according to the order in which they
were granted) shall be treated as nonstatutory stock options.

          4.       METHOD
OF PAYMENT.  Payment of the exercise price is
due in full upon exercise of all or any part of your option.  You may elect to make payment of the
exercise price by one or more of the following:

          (a)      by cash or check; or

          (b)      in the Company’s sole
discretion at the time your option is exercised and provided that at the time
of exercise the Common Stock is publicly traded and quoted regularly in The Wall
Street Journal,  pursuant to a program developed under
Regulation T as promulgated by the Federal Reserve Board that, prior to the
issuance of Common Stock, results in either the receipt of cash (or check) by
the Company or the receipt of irrevocable instructions to pay the aggregate
exercise price to the Company from the sales proceeds.

          5.       WHOLE
SHARES.  You may exercise your option only for whole
shares of Common Stock.

          6.       SECURITIES
LAW COMPLIANCE.  Notwithstanding anything to the
contrary contained herein, you may not exercise your option unless the shares
of Common Stock issuable upon such exercise are then registered under the
Securities Act or, if such shares of Common Stock are not then so registered,
the Company has determined that such exercise and issuance would be exempt from
the registration requirements of the Securities Act.  The exercise of your option must also comply with other
applicable laws and regulations governing your option, and you may not exercise
your option if the Company determines that such exercise would not be in
material compliance with such laws and regulations.

          7.       TERM.  You may not exercise your option before the
commencement of its term or after its term expires.  The term of your option commences on the Date of Grant and
expires upon the earliest of
the following:

          (a)      three (3) months after
the termination of your Continuous Service for any reason other than Disability
or death, provided that if during any part of such three- (3-) month period you
may not exercise your option solely because of the condition set forth in the
preceding paragraph relating to “Securities Law Compliance,” your option shall
not expire until the earlier of the Expiration Date or until it shall have been
exercisable for an aggregate period of three (3) months after the termination
of your Continuous Service;

          (b)      twelve (12) months
after the termination of your Continuous Service due to your Disability;

          (c)      twelve (12) months
after your death if you die either during your Continuous Service;

          (d)      the Expiration Date
indicated in your Grant Notice; or

          (e)      the day before the
tenth (10th) anniversary of the Date of Grant.

          If your option is an incentive stock option, note that,
to obtain the federal income tax advantages associated with an “incentive stock
option,” the Code requires that at all times beginning on the date of grant of your option and ending on
the day three (3) months before the date of your option’s exercise, you must be
an employee of the Company or an Affiliate, except in the event of your death
or Disability.  The Company has provided
for extended exercisability of your option under certain circumstances for your
benefit but cannot guarantee that your option will necessarily be treated as an
“incentive stock option” if you continue to provide services to the Company or
an Affiliate as a Consultant or Director after your employment terminates or if
you otherwise exercise your option more than three (3) months after the date
your employment terminates.

          8.       EXERCISE.

          (a)      You may exercise the
vested portion of your option (and the unvested portion of your option if your
Grant Notice so permits) during its term by delivering a Notice of Exercise (in
a form designated by the Company) together with the exercise price to the
Secretary of the Company, or to such other person as the Company may designate,
during regular business hours, together with such additional documents as the
Company may then require.

          (b)      By exercising your
option you agree that, as a condition to any exercise of your option, the
Company may require you to enter into an arrangement providing for the payment
by you to the Company of any tax withholding obligation of the Company arising
by reason of (1) the exercise of your option, (2) the lapse of any substantial
risk of forfeiture to which the shares of Common Stock are subject at the time
of exercise, or (3) the disposition of shares of Common Stock acquired upon
such exercise.

          (c)      If your option is an
incentive stock option, by exercising your option you agree that you will
notify the Company in writing within fifteen (15) days after the date of any
disposition of any of the shares of the Common Stock issued upon exercise of
your option that occurs within two (2) years after the date of your option
grant or within one (1) year after such shares of Common Stock are transferred
upon exercise of your option.

          9.       TRANSFERABILITY.  Your option is not transferable, except by
will or by the laws of descent and distribution, and is exercisable during your
life only by you.  Notwithstanding the
foregoing, by delivering written notice to the Company, in a form satisfactory
to the Company, you may designate a third party who, in the event of your
death, shall thereafter be entitled to exercise your option.

          10.     OPTION
NOT A SERVICE CONTRACT.  Your option
is not an employment or service contract, and nothing in your option shall be
deemed to create in any way whatsoever any obligation on your part to continue
in the employ of the Company or an Affiliate, or of the Company or an Affiliate
to continue your employment.  In
addition, nothing in your option shall obligate the Company or an Affiliate,
their respective stockholders, Boards of Directors, Officers or Employees to
continue any relationship that you might have as a Director or Consultant for
the Company or an Affiliate.

          11.     WITHHOLDING
OBLIGATIONS.

                    (a)      At the time you
exercise your option, in whole or in part, or at any time thereafter as
requested by the Company, you hereby authorize withholding from payroll and any
other amounts payable to you, and otherwise agree to make adequate provision
for (including by means of a “cashless exercise” pursuant to a program
developed under Regulation T as promulgated by the Federal Reserve Board to the
extent permitted by the Company), any sums required to satisfy the federal,
state, local and foreign tax withholding obligations of the Company or an
Affiliate, if any, which arise in connection with your option.

                    (b)      Upon your request and
subject to approval by the Company, in its sole discretion, and compliance with
any applicable conditions or restrictions of law, the Company may withhold from
fully vested shares of Common Stock otherwise issuable to you upon the exercise
of your option a number of whole shares of Common Stock having a Fair Market
Value, determined by the Company as of the date of exercise, not in excess of
the minimum amount of tax required to be withheld by law.  If the date of determination of any tax
withholding obligation is deferred to a date later than the date of exercise of
your option, share withholding pursuant to the preceding sentence shall not be
permitted unless you make a proper and timely election under Section 83(b)
of the Code, covering the aggregate number of shares of Common Stock acquired
upon such exercise with respect to which such determination is otherwise deferred,
to accelerate the determination of such tax withholding obligation to the date
of exercise of your option. 
Notwithstanding the filing of such election, shares of Common Stock
shall be withheld solely from fully vested shares of Common Stock determined as
of the date of exercise of your option that are otherwise issuable to you upon
such exercise.  Any adverse consequences
to you arising in connection with such share withholding procedure shall be
your sole responsibility.

                    (c)      You may not exercise
your option unless the tax withholding obligations of the Company and/or any
Affiliate are satisfied.  Accordingly,
you may not be able to exercise your option when desired even though your
option is vested, and the Company shall have no obligation to issue a certificate
for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein.

          12.     NOTICES.  Any notices provided for in your option or
the Plan shall be given in writing and shall be deemed effectively given upon receipt
or, in the case of notices delivered by mail by the Company to you, five (5)
days after deposit in the United States mail, postage prepaid, addressed to you
at the last address you provided to the Company.

          13.     GOVERNING
PLAN DOCUMENT.  Your option is subject to all
the provisions of the Plan, the provisions of which are hereby made a part of
your option, and is further subject to all interpretations, amendments, rules
and regulations which may from time to time be promulgated and adopted pursuant
to the Plan.  In the event of any
conflict between the provisions of your option and those of the Plan, the
provisions of the Plan shall control.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]